Nova’s expertise includes testing for the presence of MRSA on environmental surfaces, clean room surfaces, food preparation surfaces, manufacturing surfaces, and product surfaces.
Nova’s expertise also includes testing the efficacy of your antimicrobial, novel antibiotic, medical device, disinfectant, or impregnated product against MRSA.
Nova is one of the first independent laboratories to receive NARSA approval. NARSA approval allows Nova to help our clients provide products and services that fight the emergence of new disease-causing microorganisms. As a NARSA registered laboratory, Nova can access the central repository of isolates for investigative studies. The Network on Antimicrobial Resistance in Staphylococcus aureus (NARSA), developed and supported by the U.S. Department of Health & Human Services, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), is a multidisciplinary international network of basic scientists, clinical microbiologists, and clinical investigators that focus on S. aureus and other staphylococcal species that exhibit antimicrobial resistance. NARSA is responsible for tracking and procuring staphylococcal isolates (including S. aureus and the coagulase-negative staphylococci) with reduced susceptibility to vancomycin (MIC’s > 4 mg/ml) for inclusion into a central repository (NARSA Repository).
(MRSA) Testing Services
- GLP Studies
- Minimal Inhibitory Concentration, MIC
- Minimum Bactericidal Concentration, MBC
- Disinfectant Efficacy Testing
- Use Dilution Testing
- AOAC Testing